Article Text

Download PDFPDF
Coronary artery bypass grafting for triple vessel disease in cardiac amyloidosis
  1. Indira Acharya1,
  2. John J Liang2 and
  3. Christopher J Haas3,4
  1. 1Department of Internal Medicine, MedStar Union Memorial Hospital, Baltimore, Maryland, USA
  2. 2Pathology, MedStar Washington Hospital Center, Washington, DC, USA
  3. 3Internal Medicine, MedStar Harbor Hospital, Baltimore, Maryland, USA
  4. 4Department of Internal Medicine, MedStar Franklin Square Medical Center, Baltimore, Maryland, USA
  1. Correspondence to Dr Indira Acharya; acharyaindira99{at}


Cardiac amyloidosis is a rare condition with an estimated incidence of 18–55 per 100 000 person-years. It is associated with either immunoglobulin light chain (AL) or transthyretin amyloid (ATTR), both of which result in a restrictive cardiomyopathy complicated initially by diastolic dysfunction and subsequently followed by biventricular systolic heart failure. Untreated cardiac amyloidosis carries an extremely poor prognosis with an estimated median survival time of less than 1 year in AL and 4 years in ATTR amyloidosis. This is the sixth described report of coronary artery bypass grafting in patients with underlying cardiac amyloidosis.

  • Arrhythmias
  • Cardiovascular system
  • Haematology (drugs and medicines)
  • Chemotherapy
  • Pathology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors IA, JL and CH were responsible for drafting of the text, sourcing and editing of clinical images, investigation results, drawing original diagrams and algorithms, critical revision for important intellectual content, and gave final approval of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.